Companies › Xiamen Amoytop Biotech
3 active drug programs in 8 registered trials: 3 Phase 3, 3 Phase 2, 1 Phase 1, 1 Phase 4; Infectious disease, Metabolic and endocrine, Other, Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Inpegsomatropin Injection Pegylated recombinant human growth hormone (long-acting GH analog) | GH1 | Phase 3 | Small for Gestational Age; Turner Syndrome; Idiopathic Short Stature; Adult Growth Hormone Deficiency | Dec 2027 |
| Peginterferon Alfa-2B Interferon alpha/beta receptor agonist | IFNAR1, IFNAR2 | Phase 2 | Essential Thrombocythemia; Hepatitis B, Chronic; Malignant Melanoma | Sep 2027 |
| ACT201 Injection | – | Phase 1 | Chronic Hepaititis B | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05182463 | Peginterferon Alfa-2B | Phase 4 | Hepatitis B, Chronic | Infectious disease | Dec 2026 |
| NCT07741461 | ACT201 Injection | Phase 1 | Chronic Hepaititis B | Infectious disease | Mar 2027 |
| NCT06552429 | Peginterferon Alfa-2B | Phase 2 | Essential Thrombocythemia | Oncology | Sep 2027 |
| NCT07551804 | Inpegsomatropin Injection | Phase 2 | Adult Growth Hormone Deficiency | Metabolic and endocrine | Dec 2027 |
| NCT07309562 | Inpegsomatropin Injection | Phase 3 | Small for Gestational Age | Other | Mar 2028 |
| NCT07614152 | Inpegsomatropin Injection | Phase 3 | Turner Syndrome | Other | Mar 2028 |
| NCT06927310 | Inpegsomatropin Injection | Phase 3 | Idiopathic Short Stature | Metabolic and endocrine | Jun 2028 |
| NCT00539591 | Peginterferon Alfa-2B | Phase 2 | Malignant Melanoma | Oncology | May 2031 |
SK Bioscience Immorna Biotherapeutics Kexing Biopharm GC Biopharma Huahui Health
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.